Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates and infants ≤3 months, with gestational age ≥28 weeks~* Documented or presumed (or at risk of) bacterial infections, and currently receiving antibiotic treatment~* Expected to survive beyond the first 7 days after enrollment~* Sufficient vascular access to receive study drug, and to allow blood sampling at a site separate from the study drug infusion site~* Parent's / legally acceptable representative's informed consent to participate in the study~Exclusion Criteria:~* Major birth defect or malformation syndrome~* Proven presence of an immunodeficiency~* HIV or other congenital viral or fungal infection~* Significant laboratory abnormalities including: hematocrit \<20%; absolute neutrophil count \<0.5x10⁹/L; platelet count \< 50x10⁹/L; alanine aminotransferase or aspartate aminotransferase \>3 times the age-specific upper limit of normal~* Impaired renal function or known significant renal disease~* Any condition which would make the subject or caregiver, in the opinion of the investigator, unsuitable for the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- Ceftobiprole (Type: EXPERIMENTAL): Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for intravenous administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.

Based on this trial design, predict the completion outcome and termination type (if applicable).